1. Pfizer International, Inc.: T-1551. Investigator Reference Manual. New York (U.S.A.), Jan. 24, 1979.
2. Jones, R. N., Fuchs, P. C., Barry, A. L., Gavan, T. L., Gerlach, E. H., Sommers, H. M. Antimicrobial activity and spectrum of cefoperazone against recent clinical isolates. Clin. Therap. 3 (1980) 14–23.
3. Hall, W. H., Opper, B. J., Gerling, D. N. Comparative activities of the oxa-β-lactam LY 127935, cefotaxime, cefoperazone, cefamandole and ticarcillin against multiply resistant gram-negative bacilli. Antimicrob. Agents Chemother. 17 (1980) 273–279.
4. Mitsuhashi, S., Minami, S., Matsubara, N., Yotsuji, A., Kurashige, S., Saikawa, I. In vitro andin vivo activity of cefoperazone. Clin. Therap. 3 (1980) 1–13.
5. Williams, R. J., Williams, J. D.: Activity of three cephalosporins and an oxa-β-lactam compound againstPseudomonas aeruginosa. Current Chemotherapy and Infectious Disease, proc. 11th ICC & the 19th ICAAC, Boston 1979, 87–89.